1. Medtech Insight

Advanced Patient Monitoring Systems

Manufacturers of patient monitoring equipment are responding to a challenging hospital environment. They're providing advanced portable and telemetry monitoring systems that enable the continuous monitoring of critically ill patients, regardless of their location within the hospital, and often at a lower cost than could be achieved using traditional bedside systems. Portable and telemetry systems are two of the highest growth segments in the US patient monitoring market, according to Windhover Information/Medtech Insight's recently published report, US Markets for Patient Monitoring Products, which forecasts compound annual growth rates (CAGR) of 8.5% and 13.0%, respectively, in these segments through 2012.

It’s no news that hospitals are under pressure; the demand for critical care is growing dramatically as the average acuity of hospitalized patients rises with the increasing elderly population. At the same time, there is an acute shortage of registered nurses. Fortunately, this is exactly the sort of problem that lends itself to technological solutions, and manufacturers of patient monitoring equipment are responding to this challenging environment by providing advanced portable and telemetry monitoring systems that enable hospitals to provide the continuous monitoring of critically ill patients, regardless of their location within the hospital, and often at a lower cost than could be achieved using traditional bedside systems.

Portable and telemetry systems are two of the highest growth segments in the US patient monitoring market, according to Windhover...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

Terumo’s $1.5Bn Buyout Of OrganOx Vaults Company Into Organ Preservation Market

 
• By Marion Webb

Terumo will acquire OrganOx for about $1.5bn, adding the only FDA-cleared liver normothermic perfusion device to its portfolio. Analysts don’t expect the buyout to have a significant impact on competition, but the deal marks a strategic shift for Terumo into transplant medicine.

Study Finds Public Companies Behind Most Recalled AI Devices

 
• By Elizabeth Orr

A Johns Hopkins University study found publicly traded companies are responsible for 90% of recalled AI-powered medical devices. The study attributes this link to lower clinical validation, especially among smaller companies, and advocates for increased clinical trials to enhance device safety.

Four-Year Waits, 60-Page NCDs: Consultant Urges Medicare Overhaul

 
• By Elizabeth Orr

Medicare’s device coverage process is “a system in crisis,” consultant Bruce Quinn warned at the NextGen Dx Summit. He criticized bloated NCDs, stalled advisory committees, and years-long delays, urging CMS to streamline LCDs and adopt a six-month “fast-track” model to speed innovation access.